Eaton Vance Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $22.3M | Sell |
293,532
-2,508
| -0.8% | -$208K | 0.03% | 413 |
|
|
2022
Q2 | $25M | Sell |
296,040
-15,583
| -5% | -$1.37M | 0.04% | 408 |
|
|
2022
Q1 | $27.3M | Buy |
311,623
+56,343
| +22% | +$4.88M | 0.03% | 432 |
|
|
2021
Q4 | $22.3M | Buy |
255,280
+11,682
| +5% | +$970K | 0.03% | 450 |
|
|
2021
Q3 | $19.4M | Sell |
243,598
-5,393
| -2% | -$485K | 0.03% | 432 |
|
|
2021
Q2 | $22.7M | Sell |
248,991
-14,083
| -5% | -$1.25M | 0.03% | 431 |
|
|
2021
Q1 | $22.5M | Sell |
263,074
-22,201
| -8% | -$1.99M | 0.03% | 416 |
|
|
2020
Q4 | $26.9M | Buy |
285,275
+1,154
| +0.4% | +$101K | 0.04% | 365 |
|
|
2020
Q3 | $24.7M | Buy |
284,121
+2,881
| +1% | +$250K | 0.05% | 324 |
|
|
2020
Q2 | $24.6M | Sell |
281,240
-3,470
| -1% | -$300K | 0.05% | 302 |
|
|
2020
Q1 | $23.5M | Sell |
284,710
-4,747
| -2% | -$424K | 0.06% | 271 |
|
|
2019
Q4 | $27.4M | Buy |
289,457
+4,555
| +2% | +$409K | 0.05% | 281 |
|
|
2019
Q3 | $24.8M | Buy |
284,902
+11,632
| +4% | +$1.04M | 0.05% | 278 |
|
|
2019
Q2 | $25M | Sell |
273,270
-136,794
| -33% | -$11.6M | 0.05% | 270 |
|
|
2019
Q1 | $35.3M | Buy |
410,064
+323
| +0.1% | +$25.9K | 0.08% | 230 |
|
|
2018
Q4 | $31.5M | Buy |
409,741
+106,467
| +35% | +$8.29M | 0.08% | 215 |
|
|
2018
Q3 | $23.4M | Buy |
303,274
+464
| +0.2% | +$34.3K | 0.05% | 266 |
|
|
2018
Q2 | $20.5M | Sell |
302,810
-317,719
| -51% | -$21.9M | 0.05% | 273 |
|
|
2018
Q1 | $45M | Buy |
620,529
+302,794
| +95% | +$23.1M | 0.06% | 259 |
|
|
2017
Q4 | $23.9M | Sell |
317,735
-33
| -0% | -$2.49K | 0.06% | 255 |
|
|
2017
Q3 | $24.4M | Sell |
317,768
-599
| -0.2% | -$45.2K | 0.06% | 241 |
|
|
2017
Q2 | $23.8M | Sell |
318,367
-7,824
| -2% | -$555K | 0.06% | 240 |
|
|
2017
Q1 | $21.7M | Sell |
326,191
-3,252
| -1% | -$217K | 0.06% | 240 |
|
|
2016
Q4 | $21.5M | Buy |
329,443
+499
| +0.2% | +$32.4K | 0.06% | 222 |
|
|
2016
Q3 | $23.3M | Sell |
328,944
-4,227
| -1% | -$308K | 0.07% | 205 |
|
|
2016
Q2 | $24.6M | Sell |
333,171
-6,785
| -2% | -$469K | 0.07% | 198 |
|
|
2016
Q1 | $22.1M | Sell |
339,956
-11,837
| -3% | -$805K | 0.07% | 205 |
|
|
2015
Q4 | $27.1M | Sell |
351,793
-391
| -0.1% | -$31.1K | 0.08% | 187 |
|
|
2015
Q3 | $29M | Buy |
352,184
+4,510
| +1% | +$401K | 0.09% | 180 |
|
|
2015
Q2 | $30.6M | Sell |
347,674
-34,627
| -9% | -$3.18M | 0.09% | 173 |
|
|
2015
Q1 | $33.8M | Buy |
382,301
+45,629
| +14% | +$4.05M | 0.1% | 164 |
|
|
2014
Q4 | $28M | Sell |
336,672
-26,932
| -7% | -$2.23M | 0.08% | 181 |
|
|
2014
Q3 | $30.7M | Buy |
363,604
+106,094
| +41% | +$8.58M | 0.09% | 172 |
|
|
2014
Q2 | $20.9M | Sell |
257,510
-2,203
| -0.8% | -$173K | 0.06% | 214 |
|
|
2014
Q1 | $19.8M | Sell |
259,713
-5,878
| -2% | -$428K | 0.06% | 220 |
|
|
2013
Q4 | $19.1M | Sell |
265,591
-5,723
| -2% | -$398K | 0.05% | 227 |
|
|
2013
Q3 | $18.6M | Sell |
271,314
-10,531
| -4% | -$697K | 0.06% | 217 |
|
|
2013
Q2 | $17.9M | Buy |
+281,845
| New | +$18.3M | 0.05% | 210 |
|
Other funds holding NVS
Eaton Vance Management's NVS Position: Q3 2022 in Review
Eaton Vance Management reduced its Novartis (NVS) stake by 0.85% in Q3 2022, selling an estimated $208K and leaving 293,532 shares worth $22.3M. The position accounts for 0.03% of the portfolio, ranked #413.
Eaton Vance Management first reported a position in NVS in Q2 2013 and has held it in 38 quarters since. The position peaked at $45M in Q1 2018. 1,088 funds tracked by Wall St. Rank hold NVS as of Q3 2022.
- Eaton Vance Management held 293,532 shares of Novartis worth $22.3M as of Q3 2022.
- Eaton Vance Management sold 2,508 Novartis shares in Q3 2022, an estimated $208K.
- Novartis made up 0.03% of Eaton Vance Management's portfolio in Q3 2022, its #413 holding.
- Eaton Vance Management first reported a position in Novartis in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Novartis position peaked at $45M in Q1 2018.
- 1,088 funds tracked by Wall St. Rank held Novartis as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.